Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
More than 1.6 million people die globally from lung cancer each year1
ALK anaplastic lymphoma kinase is an important biomarker found in non-small cell lung cancer (NSCLC). Its detection and inhibition can help shrink tumors in some ALK-positive pati... Diagnostics, Biopharmaceuticals, Oncology, FDA Roche Group, VENTANA ALK, CDx Assay, ZYKADIA, ceritinib, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals